Finance

Lists
Q3 2026 earnings • in 4 days
See details
EW:NYSE
Edwards Lifesciences Corp
$92.01
-2.57%
(-2.43) 1D
$92.01
0.00% (0.00)
After hours
Closed: Oct 30, 4:00:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EW...
Open
$94.55
High
$95.34
Low
$91.87
Mkt. cap
53.03B
Avg. vol.
3.54M
Volume
6.04M
P/E ratio
53.23
52-wk high
$96.29
52-wk low
$74.66
EPS
$1.73
Beta
0.87
Shares outstanding
576.40M
No. of employees
16K
Open
$94.55
High
$95.34
Low
$91.87
Mkt. cap
53.03B
Avg. vol.
3.54M
Volume
6.04M
P/E ratio
53.23
52-wk high
$96.29
52-wk low
$74.66
EPS
$1.73
Beta
0.87
Shares outstanding
576.40M
No. of employees
16K
News stories
From web sources and news partners
Profile
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
About Edwards Lifesciences Corp
CEO-
Employees16K
Founded1958
HeadquartersIrvine, California, United States
SectorMedical device
Websiteedwards.com
Analyst ratings
Based on 11 analysts giving stock ratings to EW in the past 3 months
Strong buy
Buy
10
Hold
1
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for EW in the last 3 months.
Highest
Current $92.01
$110.00 (+19.55%)
Average
$104.60 (+13.68%)
Lowest
$85.00 (-7.62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Josh Jennings
TD Cowen
Buy
Reiterated
$104.00
+13%
10/27/2026
Joanne Wuensch
Citi
Buy
Maintained
$110.00
+19.6%
10/21/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
$101.00
+9.8%
10/15/2026
Marie Thibault
BTIG
Buy
Reiterated
$110.00
+19.6%
10/09/2026
Patrick Wood
UBS
Buy
Maintained
$110.00
+19.6%
10/07/2026
Christopher Pasquale
Barclays
Buy
Initiated
$110.00
+19.6%
10/07/2026
Matt Miksic
Barclays
Buy
Maintained
$110.00
+19.6%
10/07/2026
Tycho Peterson
Jefferies
Buy
Initiated
$110.00
+19.6%
10/07/2026
Kendall Au
RBC Capital
Buy
Maintained
$110.00
+19.6%
10/01/2026
Adam Maeder
Piper Sandler
Buy
Maintained
$101.00
+9.8%
09/21/2026
Matthew Taylor
Jefferies
Buy
Maintained
$105.00
+14.1%
09/11/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
$85.00
-7.6%
08/03/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
$105.00
+14.1%
07/28/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
$110.00
+19.6%
07/24/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Richard Newitter
Truist Financial
Hold
Reiterated
$95.00
+3.2%
07/24/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$110.00
+19.6%
07/23/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$100.00
+8.7%
07/21/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$105.00
+14.1%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$100.00
+8.7%
07/06/2026
David Roman
Goldman Sachs
Buy
Maintained
$98.00
+6.5%
06/15/2026
Krish Sankar
TD Cowen
Buy
Reiterated
$104.00
+13%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
David Rescott
Robert W. Baird
Hold
Maintained
$87.00
-5.4%
04/24/2026
Michael Polark
Wolfe Research
Buy
Upgraded
$92.00
-0%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
$90.00
-2.2%
02/12/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$100.00
+8.7%
02/11/2026
Next call in 4 days
Thu, Nov 5, 12:00 AM
Fiscal period
Q3 2026
- / $0.74
Revenue / Est. (USD)
- / 1.68B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.55B
1.57B
1.65B
1.74B
Cost of goods sold
345.20M
343.00M
362.60M
392.40M
Cost of revenue
345.20M
343.00M
362.60M
392.40M
Research and development expenses
280.70M
267.70M
263.30M
278.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
514.60M
601.20M
522.20M
561.20M
Operating expense
782.80M
854.60M
771.30M
829.10M
Total operating expenses
1.13B
1.20B
1.13B
1.22B
Operating income
425.10M
372.00M
514.70M
519.50M
Other non operating income
1.10M
2.30M
69.90M
-25.00M
EBT including unusual items
348.40M
90.40M
459.00M
519.80M
EBT excluding unusual items
444.50M
464.00M
603.60M
511.10M
Income tax expense
56.10M
26.20M
78.30M
278.40M
Effective tax rate
16.10%
28.98%
17.06%
53.56%
Other operating expenses
-12.50M
-14.30M
-14.20M
-11.00M
Net income
291.10M
91.20M
380.70M
241.90M
Net profit margin
18.74%
5.81%
23.09%
13.89%
Earnings per share
0.67
0.58
0.78
0.78
Interest and investment income
16.70M
114.20M
17.40M
15.00M
Interest expense
-
-20.40M
-
-
Net interest expenses
16.70M
93.80M
17.40M
15.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
464.30M
414.70M
555.60M
562.20M
Gain or loss from assets sale
-
-33.90M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps